Inactive Instrument

TiGenix NV Stock

Equities

TIG

BE0003864817

Biotechnology & Medical Research

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Chart TiGenix NV

Duration

Period

Style

Latest news about TiGenix NV

Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	18-03-28	RE
Takeda Pharmaceutical : Japan's Takeda hikes outlook on cancer drug sales, third quarter profit jumps	18-02-01	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	18-01-22	RE
Takeda Pharmaceutical : Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid	18-01-08	RE
Takeda Pharmaceutical : $11 billion biotech binge fuels forecasts of 2018 M&A surge	18-01-08	RE
GALAPAGOS : Maturing Belgian biotechs outshine European peers	12-10-04	RE

Press releases TiGenix NV

TiGenix : Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period (EN - NL - FR - ES)	18-07-31	PU
TiGenix : Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period	18-07-31	GL
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007	18-07-23	GL
TiGenix : Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s U.S. Reporting Obligations (EN – NL – FR – ES)	18-07-06	PU
TiGenix : Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid	18-07-06	GL

More press releases

News in other languages on TiGenix NV

TiGenix : Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait	18-07-31
Le Graph du Jour : 29% des biotechs en territoire positif depuis leur IPO sur Euronext	18-07-23
TiGenix : Takeda et TiGenix annoncent les résultats de la deuxième période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix	18-07-06
TiGenix : annonce un changement dans son conseil d'administration et son équipe de direction	18-06-13
TiGenix : Takeda et TiGenix annoncent les résultats de la première période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix et le début de la deuxième période d'accep...	18-06-06

Managers and Directors - TiGenix NV

Managers	Title	Age	Since
Wilfried Dalemans CTO	Chief Tech/Sci/R&D Officer	66	-
Koen Huygens PRN	Corporate Officer/Principal	-	01-06-30
Julian Panes PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Sebastian Wehle BRD	Director/Board Member	-	18-06-14
Jean Stephenne CHM	Chairman	75	-

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW